EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Longitudinal Control of Lipid Levels in Patients With Premature Coronary Artery Disease

Diana N Vikulova, Danielle Pinheiro-Muller, Carlos Rojas-Fernandez, Francois Leblond, Simon N Pimstone, Liam R Brunham

JACC: Advances · 2023-12 · 2 (10) · 100696

DOI: 10.1016/j.jacadv.2023.100696 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Advances, 2023-12. Verfasst von Diana N Vikulova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Heart Lung Innovation, University of British Columbia, Vancouver, Canada. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lipid-lowering therapy (LLT) is a central aspect of the treatment of patients with coronary artery disease (CAD), and the benefits of LLT accrue over time. However, there are limited real-world data on longitudinal lipid control in patients with premature CAD.

Objectives

The purpose of this study was to assess longitudinal attainment of guideline-recommended lipid goals and outcomes in a contemporary cohort of patients with premature CAD.

Methods

We enrolled males younger than 50 years and females younger than 55 years with coronary stenosis of >50% and examined achievement of lipid goals, LLT characteristics, and cardiovascular outcomes (major adverse cardiovascular event [MACE]).

Results

Of 476 patients who presented with acute coronary syndrome (ST-elevation myocardial infarction, non-ST-segment elevation myocardial infarction, unstable angina) (68%), stable angina (28%), or other symptoms, 73.2% achieved low-density lipoprotein cholesterol (LDL-C)

Schlagwörter

Stichwörter der Autor:innen

cardiovascular outcomeslongitudinal lipid controlpremature coronary artery diseasetime-weighted average exposure to LDL-C

Autor:innen und Institutionen

  • Centre for Heart Lung Innovation, University of British Columbia, Vancouver, Canada.
  • Department of Medicine, University of British Columbia, Vancouver, Canada.
  • Novartis Pharmaceuticals Canada, Dorval, Quebec, Canada.
  • Division of Cardiology, University of British Columbia, Vancouver, Canada.
  • Department of Medical Genetics, University of British Columbia, Vancouver, Canada.

Förderung

  • Canadian Institutes of Health Research

Zitieren

APA

Vikulova, D. N., Pinheiro-Muller, D., Rojas-Fernandez, C., Leblond, F., Pimstone, S. N., & Brunham, L. R. (2023). Longitudinal Control of Lipid Levels in Patients With Premature Coronary Artery Disease. JACC: Advances, 2(10), 100696. https://doi.org/10.1016/j.jacadv.2023.100696

Vancouver

Vikulova DN, Pinheiro-Muller D, Rojas-Fernandez C, Leblond F, Pimstone SN, Brunham LR. Longitudinal Control of Lipid Levels in Patients With Premature Coronary Artery Disease. JACC: Advances. 2023;2(10):100696. doi:10.1016/j.jacadv.2023.100696

BibTeX
@article{Vikulova2023,
  author = {Vikulova, Diana N and Pinheiro-Muller, Danielle and Rojas-Fernandez, Carlos and Leblond, Francois and Pimstone, Simon N and Brunham, Liam R},
  title = {Longitudinal Control of Lipid Levels in Patients With Premature Coronary Artery Disease},
  journal = {JACC: Advances},
  year = {2023},
  volume = {2},
  number = {10},
  pages = {100696},
  doi = {10.1016/j.jacadv.2023.100696}
}
Kostenlos starten →